Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on AxoGen, boosting the price target to $26.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yi Chen has given his Buy rating due to a combination of factors that highlight AxoGen’s strong financial performance and promising future prospects. The company reported impressive third-quarter results for 2025, with a 23.5% year-over-year revenue growth and a net income that surpassed expectations. This financial success is supported by the recognition of nerve allograft as a standard medical practice by several professional societies, which is expected to drive further adoption and revenue growth.
Additionally, AxoGen’s strategic market development efforts have expanded coverage and reimbursement, significantly increasing the number of covered lives and commercial payer coverage. The company’s revenue guidance for 2025 has been raised to $222.8 million, indicating at least 19% growth. Furthermore, the anticipated approval of the Avance Nerve Graft’s Biologics License Application by the FDA in 2025 could enhance market penetration and secure a 12-year exclusivity period in the U.S., bolstering AxoGen’s competitive position. These factors collectively contribute to the positive outlook and justify the Buy rating.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $34.00 price target.